title: Progress in clinical neurosciences: a forum on the early management of Parkinson's disease.
abstract: There are numerous concerns related to treatment choices involving early dopaminergic therapy in Parkinson's disease. These include the effect on the underlying progression of the neurodegenerative process as well as the development of motor complications such as fluctuations and dyskinesias. A number of recent basic and clinical studies have provided new insights but have also added confusion and controversy. This report summarizes presentations and discussion dealing with these issues from a one-day symposium involving Canadian Movement Disorders neurologists.
authors.affiliation: Division of Neurology, Department of Medicine, University of Toronto, Toronto Western Hospital, Canada.
authors.forename: Anthony E
authors.initials: AE
authors.lastname: Lang
authors.forename: Janis
authors.initials: J
authors.lastname: Miyasaki
authors.forename: C Warren
authors.initials: CW
authors.lastname: Olanow
authors.forename: A Jon
authors.initials: AJ
authors.lastname: Stoessl
authors.forename: Oksana
authors.initials: O
authors.lastname: Suchowersky
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D009069:Movement Disorders / Q000209:etiology / Q000628:therapy; D010300:Parkinson Disease / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007980:Levodopa